新型碳青霉烯类药物多利培南的体外抗菌活性
In vitro antimicrobial activity of doripenem, a new carbapenem.
作者信息
Ge Yigong, Wikler Matthew A, Sahm Daniel F, Blosser-Middleton Renée S, Karlowsky James A
机构信息
Peninsula Pharmaceuticals, Alameda, California 94502, USA.
出版信息
Antimicrob Agents Chemother. 2004 Apr;48(4):1384-96. doi: 10.1128/AAC.48.4.1384-1396.2004.
Abstract
The doripenem MICs at which 90% of the tested strains were inhibited ranged from 0.03 to 1 microg/ml for 10 species of Enterobacteriaceae (n = 351), from 0.03 to 0.12 microg/ml for oxacillin-susceptible staphylococci (n = 119), from 4 to 32 microg/ml for oxacillin-resistant staphylococci (n = 64), from < or =0.008 to 0.06 microg/ml for penicillin-susceptible streptococci (n = 132), and from 1 to 4 microg/ml for penicillin-resistant streptococci (n = 51). Overall, doripenem demonstrated in vitro activity similar to that of meropenem against gram-negative pathogens and to that of imipenem against gram-positive pathogens.
摘要
对于10种肠杆菌科细菌（n = 351），能抑制90%受试菌株的多利培南最低抑菌浓度（MIC）范围为0.03至1微克/毫升；对于对苯唑西林敏感的葡萄球菌（n = 119），该范围为0.03至0.12微克/毫升；对于对苯唑西林耐药的葡萄球菌（n = 64），为4至32微克/毫升；对于对青霉素敏感的链球菌（n = 132），为≤0.008至0.06微克/毫升；对于对青霉素耐药的链球菌（n = 51），为1至4微克/毫升。总体而言，多利培南在体外对革兰氏阴性病原体的活性与美罗培南相似，对革兰氏阳性病原体的活性与亚胺培南相似。
相似文献
1
In vitro antimicrobial activity of doripenem, a new carbapenem.新型碳青霉烯类药物多利培南的体外抗菌活性
Antimicrob Agents Chemother. 2004 Apr;48(4):1384-96. doi: 10.1128/AAC.48.4.1384-1396.2004.
2
Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.阿根廷关于哌拉西林-他唑巴坦对从住院患者中分离出的特定细菌菌株的体外比较活性的多中心合作研究。
Diagn Microbiol Infect Dis. 2003 Nov;47(3):527-37. doi: 10.1016/s0732-8893(03)00131-7.
3
Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.哌拉西林/他唑巴坦的抗菌效力及抗菌谱更新（2000年）：重点关注其对耐药菌群体及通常未作检测的引起社区获得性呼吸道感染的菌种的活性。
Diagn Microbiol Infect Dis. 2002 May;43(1):49-60. doi: 10.1016/s0732-8893(02)00358-9.
4
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.多利培南（S-4661），一种新型碳青霉烯类抗生素：对当代病原体的比较活性，包括杀菌作用和初步体外方法评估。
J Antimicrob Chemother. 2004 Jul;54(1):144-54. doi: 10.1093/jac/dkh298. Epub 2004 Jun 9.
5
Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.美罗培南、亚胺培南和哌拉西林/他唑巴坦对 1071 株临床分离菌的体外比较活性：一项法国多中心研究。
BMC Infect Dis. 2010 Mar 18;10:72. doi: 10.1186/1471-2334-10-72.
6
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.ACHN-490 单独及与其他药物联合对铜绿假单胞菌的活性。
Antimicrob Agents Chemother. 2011 May;55(5):2463-5. doi: 10.1128/AAC.01390-10. Epub 2011 Jan 31.
7
Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam.铜绿假单胞菌对碳青霉烯类和哌拉西林/他唑巴坦的耐药模式。
J Chemother. 1999 Apr;11(2):93-6. doi: 10.1179/joc.1999.11.2.93.
8
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.多利培南（一种用于治疗由革兰氏阴性菌引起的难治性感染的碳青霉烯类药物）对来自美国的近期临床分离株的体外活性。
Antimicrob Agents Chemother. 2008 Dec;52(12):4388-99. doi: 10.1128/AAC.00381-08. Epub 2008 Sep 8.
9
Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.一家三级护理医院中哌拉西林/他唑巴坦的体外比较评估
J Chemother. 1997 Oct;9(5):336-40. doi: 10.1179/joc.1997.9.5.336.
10
In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles.哌拉西林/他唑巴坦及其他广谱抗生素对不列颠群岛住院患者体内细菌的体外活性
Int J Antimicrob Agents. 2003 Jul;22(1):14-27. doi: 10.1016/s0924-8579(03)00108-0.
引用本文的文献
1
Doripenem in the Treatment of Patients with Nosocomial Pneumonia: A Meta-Analysis.多利培南治疗医院获得性肺炎患者的荟萃分析
J Clin Med. 2022 Jul 11;11(14):4014. doi: 10.3390/jcm11144014.
2
Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations.多利培南在中国健康受试者中的药代动力学与安全性及蒙特卡洛剂量模拟
Antibiotics (Basel). 2022 Jul 16;11(7):958. doi: 10.3390/antibiotics11070958.
3
Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function.多利培南在健康韩国人中的药代动力学及蒙特卡洛模拟以探索肾功能正常和增强患者的最佳给药方案
Ther Drug Monit. 2018 Aug;40(4):425-434. doi: 10.1097/FTD.0000000000000528.
4
Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age.开放标签研究以评估多利培南在实际年龄小于12周婴儿中的单剂量药代动力学、安全性和耐受性。
Antimicrob Agents Chemother. 2015 Aug;59(8):4742-9. doi: 10.1128/AAC.00485-15. Epub 2015 May 26.
5
New antibiotics for bad bugs: where are we?新型抗生素应对耐药菌：进展如何？
Ann Clin Microbiol Antimicrob. 2013 Aug 28;12:22. doi: 10.1186/1476-0711-12-22.
6
Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.在体外药代动力学模型中评估多利培南对铜绿假单胞菌和鲍曼不动杆菌的抗菌作用和耐药性产生的药效动力学。
Antimicrob Agents Chemother. 2012 Oct;56(10):5009-15. doi: 10.1128/AAC.06111-11. Epub 2012 Jun 19.
7
In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.法国教学医院临床分离株的多利培南体外抗菌活性：建议使用抑菌环直径分界点。
Eur J Clin Microbiol Infect Dis. 2011 Apr;30(4):475-82. doi: 10.1007/s10096-010-1117-6. Epub 2010 Nov 19.
8
Comparison of broth microdilution, agar dilution, and Etest for susceptibility testing of doripenem against gram-negative and gram-positive pathogens.肉汤微量稀释法、琼脂稀释法和 Etest 法检测多利培南对革兰阴性和革兰阳性病原体的药敏试验比较。
J Clin Microbiol. 2010 Sep;48(9):3353-7. doi: 10.1128/JCM.00494-10. Epub 2010 Jun 30.
9
Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates.多利培南对产超广谱β-内酰胺酶肠杆菌科和铜绿假单胞菌分离株的活性。
Eur J Clin Microbiol Infect Dis. 2010 Sep;29(9):1179-81. doi: 10.1007/s10096-010-0974-3. Epub 2010 Jun 4.
10
Characteristics of doripenem: a new broad-spectrum antibiotic.多利培南的特性：一种新型广谱抗生素。
Drug Des Devel Ther. 2009 Sep 21;3:173-90. doi: 10.2147/dddt.s3083.
本文引用的文献
1
Antimicrobial-induced release of endotoxin from Pseudomonas aeruginosa: comparison of in vitro and animal models.抗菌药物诱导铜绿假单胞菌释放内毒素：体外模型与动物模型的比较
J Antimicrob Chemother. 2003 Feb;51(2):353-9. doi: 10.1093/jac/dkg042.
2
In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections.新型胃肠外给药碳青霉烯类药物S-4661对从复杂性尿路感染患者中分离出的泌尿系统病原体的体外抗菌活性。
J Chemother. 2002 Apr;14(2):155-60. doi: 10.1179/joc.2002.14.2.155.
3
Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens.
Chemotherapy. 2000 May-Jun;46(3):184-7. doi: 10.1159/000007276.
4
In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem.新型口服碳青霉烯类药物CS-834的体外和体内抗菌活性
Antimicrob Agents Chemother. 1998 Mar;42(3):555-63. doi: 10.1128/AAC.42.3.555.
5
In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.新型碳青霉烯类药物S-4661的体外和体内抗菌活性
Antimicrob Agents Chemother. 1998 Jan;42(1):94-9. doi: 10.1128/AAC.42.1.94.
6
In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem.新型抗假单胞菌碳青霉烯类药物ER-35786的体外和体内抗菌活性
Antimicrob Agents Chemother. 1997 Feb;41(2):298-307. doi: 10.1128/AAC.41.2.298.
7
Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I.
J Antimicrob Chemother. 1996 May;37(5):1034-6. doi: 10.1093/jac/37.5.1034.
8
A novel 1 beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems.一种新型1β-甲基碳青霉烯抗生素，S-4661。2-(5-取代吡咯烷-3-基硫基)-1β-甲基碳青霉烯类的合成及构效关系
J Antibiot (Tokyo). 1996 Feb;49(2):199-209. doi: 10.7164/antibiotics.49.199.
9
In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I.新型碳青霉烯类药物LJC10,627对脱氢肽酶I稳定的体外及体内活性
Antimicrob Agents Chemother. 1991 Jan;35(1):203-7. doi: 10.1128/AAC.35.1.203.
Zotero 插件